Novavax Inc NVAX
Analyst Ratings
- Consensus
- Moderate Buy — 4 Buy · 1 Hold · 1 Sell (6 analysts)
- Avg. Price Target
- $14.00 (+54.7% upside)
Key Stats
- Today's Range
- $8.91 – $9.18
- 50-Day Range
- $7.15 – $10.12
- 52-Week Range
- $6.20 – $11.97
- Volume
- 3.43 million shs
- Average Volume
- 3.89 million shs
- Market Cap
- $1.49 billion
- P/E Ratio
- —
- Dividend Yield
- 14.09%
Valuation
- P/E Ratio
- —
- Price / Book
- -7.83
- Price / Sales
- 3.61
Dividend
- Dividend Yield
- 14.09%
- Annual Dividend
- $1.27
- Payout Ratio
- —
- Ex-Dividend Date
- 2007-12-13
Short Interest
- Short Interest
- 25.98%
- Days to Cover
- 4.92
Financials (TTM)
- Revenue
- $413.80 million
- Net Income
- $-247,730,000
- Net Margin
- -59.87%
- Return on Equity
- 129.90%
- Debt-to-Equity
- -1.53
About Novavax Inc
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
Related Stocks
Compare head-to-head: NVAX vs AMGN·NVAX vs MRNA·NVAX vs HALO·NVAX vs KRYS
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.